176 related articles for article (PubMed ID: 24327018)
1. Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models.
Zhang H; Hylander BL; LeVea C; Repasky EA; Straubinger RM; Adjei AA; Ma WW
Br J Cancer; 2014 Jan; 110(2):320-9. PubMed ID: 24327018
[TBL] [Abstract][Full Text] [Related]
2. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
[TBL] [Abstract][Full Text] [Related]
3. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
4. Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.
Zhang K; Chu K; Wu X; Gao H; Wang J; Yuan YC; Loera S; Ho K; Wang Y; Chow W; Un F; Chu P; Yen Y
Cancer Res; 2013 Feb; 73(4):1298-307. PubMed ID: 23393200
[TBL] [Abstract][Full Text] [Related]
5. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.
Byron SA; Chen H; Wortmann A; Loch D; Gartside MG; Dehkhoda F; Blais SP; Neubert TA; Mohammadi M; Pollock PM
Neoplasia; 2013 Aug; 15(8):975-88. PubMed ID: 23908597
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of fibroblast growth factor receptor 2 attenuates proliferation and invasion of pancreatic cancer.
Matsuda Y; Yoshimura H; Suzuki T; Uchida E; Naito Z; Ishiwata T
Cancer Sci; 2014 Sep; 105(9):1212-9. PubMed ID: 24975163
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
Wang Y; Ding X; Wang S; Moser CD; Shaleh HM; Mohamed EA; Chaiteerakij R; Allotey LK; Chen G; Miyabe K; McNulty MS; Ndzengue A; Barr Fritcher EG; Knudson RA; Greipp PT; Clark KJ; Torbenson MS; Kipp BR; Zhou J; Barrett MT; Gustafson MP; Alberts SR; Borad MJ; Roberts LR
Cancer Lett; 2016 Sep; 380(1):163-73. PubMed ID: 27216979
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.
Hanes R; Munthe E; Grad I; Han J; Karlsen I; McCormack E; Meza-Zepeda LA; Stratford EW; Myklebost O
Cells; 2019 Feb; 8(2):. PubMed ID: 30795553
[No Abstract] [Full Text] [Related]
9. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors.
Sergei B; Pavel D; Aigul G; Firyuza B; Ilmira N; Ilshat M; Aida A; Refat K; Natalia A; Elena S; Vera G
Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31948066
[TBL] [Abstract][Full Text] [Related]
11. Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05).
Choi YJ; Kim HS; Park SH; Kim BS; Kim KH; Lee HJ; Song HS; Shin DY; Lee HY; Kim HG; Lee KH; Lee JL; Park KH
Cancer Res Treat; 2018 Oct; 50(4):1252-1259. PubMed ID: 29334610
[TBL] [Abstract][Full Text] [Related]
12. Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β.
Lau WM; Teng E; Huang KK; Tan JW; Das K; Zang Z; Chia T; Teh M; Kono K; Yong WP; Shabbir A; Tay A; Phua NS; Tan P; Chan SL; So JBY
Mol Cancer Ther; 2018 Jan; 17(1):232-242. PubMed ID: 28978722
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.
Eritja N; Domingo M; Dosil MA; Mirantes C; Santacana M; Valls J; Llombart-Cussac A; Matias-Guiu X; Dolcet X
Mol Cancer Ther; 2014 Apr; 13(4):776-87. PubMed ID: 24448819
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
Issa A; Gill JW; Heideman MR; Sahin O; Wiemann S; Dey JH; Hynes NE
Breast Cancer Res; 2013 Jan; 15(1):R8. PubMed ID: 23343422
[TBL] [Abstract][Full Text] [Related]
15. FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer.
Nomura S; Yoshitomi H; Takano S; Shida T; Kobayashi S; Ohtsuka M; Kimura F; Shimizu H; Yoshidome H; Kato A; Miyazaki M
Br J Cancer; 2008 Jul; 99(2):305-13. PubMed ID: 18594526
[TBL] [Abstract][Full Text] [Related]
16. Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform.
Cha JY; Maddileti S; Mitin N; Harden TK; Der CJ
J Biol Chem; 2009 Mar; 284(10):6227-40. PubMed ID: 19103595
[TBL] [Abstract][Full Text] [Related]
17. Cucurmosin induces the apoptosis of human pancreatic cancer CFPAC-1 cells by inactivating the PDGFR-β signalling pathway.
Xie J; Wang C; Zhang B; Yang A; Yin Q; Huang H; Chen M
Pharmacol Rep; 2013; 65(3):682-8. PubMed ID: 23950591
[TBL] [Abstract][Full Text] [Related]
18. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.
Huynh H; Chow PK; Tai WM; Choo SP; Chung AY; Ong HS; Soo KC; Ong R; Linnartz R; Shi MM
J Hepatol; 2012 Mar; 56(3):595-601. PubMed ID: 22027573
[TBL] [Abstract][Full Text] [Related]
19. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.
Chen ZY; Shi M; Peng LX; Wei W; Li XJ; Guo ZX; Li SH; Zhong C; Qian CN; Guo RP
J Transl Med; 2012 Dec; 10():245. PubMed ID: 23228017
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer.
Krook MA; Barker H; Chen HZ; Reeser JW; Wing MR; Martin D; Smith AM; Dao T; Bonneville R; Samorodnitsky E; Miya J; Freud AG; Monk JP; Clinton SK; Roychowdhury S
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):624-632. PubMed ID: 31043681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
